Member Info for chester18

The interesting thing will be if I’m right !

How did I know 🤔

Come on Scinv answer my question….

I know you have a sense of humour because I’ve read your posts 🤣🤣🤣

It’s just for fun Scinv do you have a problem with a late July report ?

Because we have no way of knowing that all the scans are complete for many reasons to do with clinical and health issues, I’m guessing that we will receive an Update Report from the ModiFY trial first.

SCIB1 and IScib+ will not finish clinical reporting until late June so add a few weeks for all the stats to be confirmed.

Thursday 24th July would give adequate time to build the report and have time to discuss with any potential partners before full disclosure.

Any time June is just too early.

The fact that there has been little or no news since the joint presentation with Illumina does lead me to believe Angle have been in discussions with someone.

Very good possibility that we hear about the future relationship with Illumina but not sure they could hold back news of a major tie up with AstraZeneca.

This does seem overall positive, fingers crossed 🤞

Looks like Martin Diggle is confident enough to see 9.00p as ‘top up’ bargain basement price.

He’s just added to his stockholding another £45k’s worth.

He is definitely in a better position than the rest of us to know if it’s worth an extra £45k.

Plus it may also signal that Scancell may be going into a closed period where directors cannot buy or sell .

Hi ponsonb

Yep that’s a similar time to myself. I think the toughest bit was when we were all ready to start Immunobody trials in the USA and we waited and waited. Until we were told that the TriGrid device had continued to fail at the FDA. Nothing to do with our potential melanoma cancer vaccine just the rigorous hurdles of an electrically driven medical device.

That kind of wasted 2 years and then we ran straight into Covid, just to slow us down a bit more.

So we are now very close to an investment defining set of results.

Everything being projected from Scancell is very positive. Well we need a large Pharma to listen to the rhetoric and then agree that’s it’s the ‘Nuts’.

Then we can all enjoy the journey towards a commercial product or two or three or ten.

All the best 🤞🤞

As the much anticipated data should be a much fuller picture of both trial cohorts here is a reminder of what we can expect.

SCIB1 Mono

SCIB1 + CPI

SCIB1 + double CPI

iSCIB+ double CPI Intramuscular

Modi1- Mono

Modi1- Ovarian

Modi1 - Breast Cancer

Modi1 - Head & Neck plus single CPI

Modi1 - Renal Cell Carcinoma Double CPI

Modi1 - NeoAdjuvant

Hopefully that covers everything .

iSCIB+ - Double CPI Intradermal Jan 2026

Sorry , Phase 3 Trial …… oops

Ponsonb it has felt like that following Scancell for the last ten years. However our new CEO has made it very clear that under his watch deadlines will be met.

So I’m still wondering what Mid-Year means to him ?

Jan 2026 should just be for the iSCIB+ Intradermal Cohort 4 by which time I hope we have already locked up a deal with someone to ease the cost burden of the Reg Trial followed by a large Phase4.

When is ‘Mid-Year’ to Scientists ?

Is it bang on midnight on June 30th ?

Is it somewhere between 1st June and 31st July ?

Or, is it ‘Clinical Trials Speak’ for sometime before Late August and definitely maybe this year 🫣

I’m just trying to get a sense of how expandable is ‘Mid-Year’ ….

All answers, ideas or suggestions welcome 👍

C7 was the main character on here when I plucked up the courage to add my first post.

I was welcomed by C7 and had many discussions on the pros and cons of Scancell’s possible futures.

A much regarded and respected part of this board.

😢

I am extremely hopeful that in the aftermath of the data being released I will have good reason to moan about all the Nobby Knowalls that will pop up and start telling everyone about how special Scancell are and how to conduct our investments.

Now that’s a MOAN I will look forward to …… 🤣🤣

Everyone and I include any institutions that may want to be apart of the Scancell story, are waiting for the data readouts.

I would expect that all serious long term holders are already stocked up.

The SP movements we are seeing are from those that are getting cold feet, traders and people just needing some of their investment back as cash.

It’s not a huge amount of stock being sold off but the trend is only down at the moment.

‘Mid year’ should mean June / July so we’re between 7 to 11 weeks away from a definitive set of clinical results.

Well explained, thank you Scinv

Scinv question for you.

If the injected Nivo actually improved Nivo’s affect at unmasking a solid tumour surely it would mean both the immune system and iSCIB+ would have a greater chance of infiltration.

What is the reason this would not happen, is the injected form of Nivo working in a different way ?

If the injected Nivo is more that an adjusted delivery and it actually improves outcomes it can only help iSCIB+ when combined.

Hi GG123

Totally agree, but at the same time as I am concerned that there is going to be more pain, I really hope that behind the current silence there are some serious deal making conversations going on.

About time some good news landed.

It would be fantastic for all shareholders if this all comes to pass but Angle are going to need £18m to £20m of finance to reach 2028, the effective revenue from this route.

What is absolutely essential for the current shareholders is a much quicker route to either high volume monthly revenues or a chunk of cash in the form of a deal.

The Parsotix system itself is genius and the long term revenue’s could be multi millions per year but Angle needs to cover its running costs in the very near future.

Understood, all paths lead to more Parsortix machines and cassette sales. So AI is assuming LabCorp as the possible reason for the appointment of a full time Phlebotomist but that this path to revenue for Angle is approx 2 years in the future, if it all goes well.

What is needed is a deal with cash attached asap. Then the above scenario can play out in its own time.